The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 14, 2023
Filed:
Jan. 08, 2021
Applicant:
Disc Medicine, Inc., Cambridge, MA (US);
Inventors:
Brian Richard MacDonald, Cambridge, MA (US);
Maria Gabriela Beconi, Cambridge, MA (US);
Vu Hong, Cambridge, MA (US);
Assignee:
Disc Medicine, Inc., Watertown, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61P 1/16 (2006.01); A61K 31/69 (2006.01); A61K 31/785 (2006.01); A61K 33/26 (2006.01); A61K 33/44 (2006.01); A61K 35/14 (2015.01); A61K 35/28 (2015.01); A61K 35/407 (2015.01); A61K 38/10 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/69 (2013.01); A61K 31/785 (2013.01); A61K 33/26 (2013.01); A61K 33/44 (2013.01); A61K 35/14 (2013.01); A61K 35/28 (2013.01); A61K 35/407 (2013.01); A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01);
Abstract
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.